As a response to cholestasis, many patients with PSC with advanced disease will have progressed beyond a ‘tipping point’, whereby bile acid synthesis is fully suppressed and any further therapeutic activation of the FXR–FGF19 axis will be futile. The gene discussed is FGF19; the disease is cholestasis.